Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy

Breast Cancer ◽  
2004 ◽  
Vol 11 (3) ◽  
pp. 267-275 ◽  
Author(s):  
Yoshinari Ogawa ◽  
Takuya Moriya ◽  
Yasuyuki Kato ◽  
Mitsue Oguma ◽  
Katsumi Ikeda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Endocrine Therapy ◽  
Progesterone Receptor Status ◽  
Receptor Status ◽  
Immunohistochemical Assessment

Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence

2015 ◽  
Vol 101 (4) ◽  
pp. 398-403 ◽  
Author(s):  
Giuseppe Bogina ◽  
Gianluigi Lunardi ◽  
Francesca Coati ◽  
Giuseppe Zamboni ◽  
Stefania Gori ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Locoregional Recurrence ◽  
Progesterone Receptor Status ◽  
Breast Cancer Patients ◽  
Receptor Status ◽  
Estrogen Receptor Positive

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

2003 ◽  
Vol 21 (10) ◽  
pp. 1973-1979 ◽  
Author(s):  
Valerie-Jeanne Bardou ◽  
Grazia Arpino ◽  
Richard M. Elledge ◽  
C. Kent Osborne ◽  
Gary M. Clark
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Endocrine Therapy ◽  
Multivariate Analyses ◽  
Adjuvant Endocrine Therapy ◽  
Endocrine Treatment ◽  
Receptor Status ◽  
Risk Of Death ◽  
Er Positive

Purpose: To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer. Patients and Methods: Clinical outcomes of patients in two large databases were analyzed as a function of steroid receptor status. The first database (PP), contained 3,739 patients who did not receive any systemic adjuvant therapy and 1,688 patients who received adjuvant endocrine therapy but no chemotherapy. The second database (SPORE), contained 10,444 patients who received adjuvant endocrine therapy but no chemotherapy. Biochemical ER and PgR assays were identically performed in two different central laboratories. Results: In univariate and multivariate analyses, the prognostic significance of PgR status among systemically untreated patients is modest. Among endocrine-treated patients, however, multivariate analyses, including lymph-node involvement, tumor size, and age, demonstrate that PgR status is independently associated with disease-free and overall survival. For recurrence, the reduction in relative risk (RR) was 25% for ER-positive/PgR-negative patients and 53% for ER-positive/PgR-positive patients, compared with ER-negative/PgR-negative patients (P < .0001, PP patients). Patients with ER-positive/PgR-negative tumors have a reduction in RR of death of 30% (SPORE patients) and 38% (PP patients), compared with patients with ER-negative/PgR-negative tumors (P < .0001). For ER-positive/PgR-positive tumors, the reduction of the risk of death was greater than 46% in SPORE patients and 58% in PP patients, indicating that ER-positive/PgR-positive patients derive more benefit from endocrine therapy (P < .0001). Conclusion: When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy. Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients.

Sign in / Sign up

Export Citation Format

Share Document